THC inhibits the expression of ethanol-induced locomotor sensitization in mice

Filev, Renato; Engelke, Douglas Senna; Silveira, Dartiu Xavier da; Mello, Luiz E.; Santos-Junior, Jair Guilherme

doi:10.1016/j.alcohol.2017.06.004

Cited by 16 publications

(16 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…). In the following sections, we review findings of the effects of CBD on alcohol‐related harms in human participants (Belgrave et al., ; Bird et al., ; Consroe et al., ), cell culture (Brenneman et al., ), and animal models (Filev et al., ; Gonzalez‐Cuevas et al., ; Hamelink et al., ; Liput et al., ; Viudez‐Martínez et al., ,b; Wang et al., ; Yang et al., ). Table provides a concise summary of the alcohol‐related harm and associated outcomes of the studies included in this review.…”

Section: Resultsmentioning

confidence: 99%

“…Four studies were identified examining the effects of CBD on alcohol consumption or self‐administration and processes associated with relapse and addiction (Gonzalez‐Cuevas et al., ; Viudez‐Martínez et al., ,b; Filev et al., ). One of these studies examined the effects of CBD when combined with naltrexone (Viudez‐Martínez et al., ).…”

Section: Resultsmentioning

confidence: 99%

“…Finally, 1 study examined the effect of CBD on an animal model of locomotor sensitization (Filev et al., ). The rationale for this model is that repeated administration of substances of abuse (e.g., alcohol) typically induces progressive and persistent increase in locomotor activity, even after withdrawal (Coelhoso et al., ).…”

Section: Resultsmentioning

confidence: 99%

“…Once acquired, this effect is long‐lasting and is temporally related to morphological and neurochemical changes in the mesolimbic pathway and in the encephalic nuclei interacting with this dopaminergic tract (Vanderschuren and Pierce, ). Filev and colleagues () examined the effects of 4 days of pretreatment with only CBD (2.5 mg/kg), THC (2.5 mg/kg), or the combination of both compared to vehicle. Only the THC and THC + CBD group revealed reduced expression of locomotor sensitization; no effects were observed with CBD alone.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review

Turna

Syan

Frey

et al. 2019

Alcoholism Clin & Exp Res

View full text Add to dashboard Cite

There is substantial interest in the therapeutic potential of cannabidiol (CBD), a nonpsychoactive cannabinoid found in plants of the genus Cannabis. The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a candidate pharmacotherapy for alcohol use disorder (AUD). Using a comprehensive search strategy, 303 unique potential articles were identified and 12 ultimately met criteria for inclusion (8 using rodent models, 3 using healthy adult volunteers, and 1 using cell culture). In both rodent and cell culture models, CBD was found to exert a neuroprotective effect against adverse alcohol consequences on the hippocampus. In rodent models, CBD was found to attenuate alcohol-induced hepatotoxicity, specifically, alcoholinduced steatosis. Finally, findings from preclinical rodent models also indicate that CBD attenuates cue-elicited and stress-elicited alcohol seeking, alcohol self-administration, withdrawal-induced convulsions, and impulsive discounting of delayed rewards. In human studies, CBD was well tolerated and did not interact with the subjective effects of alcohol. Collectively, given its favorable effects on alcoholrelated harms and addiction phenotypes in preclinical models, CBD appears to have promise as a candidate AUD pharmacotherapy. This is further bolstered by the absence of abuse liability and its general tolerability. A clear limitation to the literature is the paucity of human investigations. Human preclinical and clinical studies are needed to determine whether these positive effects in model systems substantively translate into clinically relevant outcomes.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review

Turna

Syan

Frey

et al. 2019

Alcoholism Clin & Exp Res

View full text Add to dashboard Cite

show abstract

“…Further animal studies show CBD (at 15 mg/kg) to effectively reduce cue and stress induced reinstatement of ethanol administration, up to 138 days post-CBD treatment (140). However, one study found CBD alone to be ineffective in attenuating ethanol sensitization, which is suggested to be the first step in drug-associated plasticity (121). Comparatively, pure THC and a 1:1 ratio of THC:CBD was found to be more efficacious in reducing ethanol sensitization.…”

Section: Cannabidiol (Cbd)mentioning

confidence: 99%

The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder

et al. 2019

View full text Add to dashboard Cite

Substance use disorder is characterized by repeated use of a substance, leading to clinically significant distress, making it a serious public health concern. The endocannabinoid system plays an important role in common neurobiological processes underlying substance use disorder, in particular by mediating the rewarding and motivational effects of substances and substance-related cues. In turn, a number of cannabinoid drugs (e.g., rimonabant, nabiximols) have been suggested for potential pharmacological treatment for substance dependence. Recently, cannabidiol (CBD), a non-psychoactive phytocannabinoid found in the cannabis plant, has also been proposed as a potentially effective treatment for the management of substance use disorder. Animal and human studies suggest that these cannabinoids have the potential to reduce craving and relapse in abstinent substance users, by impairing reconsolidation of drug-reward memory, salience of drug cues, and inhibiting the reward-facilitating effect of drugs. Such functions likely arise through the targeting of the endocannabinoid and serotonergic systems, although the exact mechanism is yet to be elucidated. This article seeks to review the role of the endocannabinoid system in substance use disorder and the proposed pharmacological action supporting cannabinoid drugs' therapeutic potential in addictions, with a focus on CBD. Subsequently, this article will evaluate the underlying evidence for CBD as a potential treatment for substance use disorder, across a range of substances including nicotine, alcohol, psychostimulants, opioids, and cannabis. While early research supports CBD's promise, further investigation and validation of CBD's efficacy, across preclinical and clinical trials will be necessary.

show abstract

Brain-Immune Mechanisms in Alcohol Use Disorder Targeting Neuroimmune Signaling in Alcohol Use Disorder: Opportunities for Translation

Grodin,

Meredith,

Burnette

et al. 2023

Alcohol and Alcohol-Related Diseases

View full text Add to dashboard Cite

THC inhibits the expression of ethanol-induced locomotor sensitization in mice

Cited by 16 publications

References 41 publications

Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review

Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review

The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder

Brain-Immune Mechanisms in Alcohol Use Disorder Targeting Neuroimmune Signaling in Alcohol Use Disorder: Opportunities for Translation

Contact Info

Product

Resources

About